Suit Says Fresenius Hid Cardiovascular Risks Posed by GranuFlo, NaturaLyte

DUBLIN, Ga. — A Georgia man has sued Fresenius North America Inc. (NYSE: FMS), alleging that his mother’s cardiovascular death was caused by the use of its GranuFlo and NaturaLyte products in her dialysis treatment.

The Sept. 14 complaint, filed in the U.S. District Court for the Southern District of Georgia, says Fresenius knew but failed to disclose of the risks presented by the dry acid products, including cardiovascular death, sudden cardiac death, cardiopulmonary arrest, heart attack and congestive heart failure.

Waddell Bishop alleges that in 2010, his mother, Frances Bishop, received dialysis treatment that included the use of …